why Salarius Pharmaceuticals Inc [SLRX] is a Good Choice for Investors After New Price Target of $3.25
Salarius Pharmaceuticals Inc [NASDAQ: SLRX] slipped around -0.01 points on Friday, while shares priced at $0.58 at the close of the session, down -1.76%. The company report on January 16, 2024 at 8:00 AM that Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders.